[{"data":1,"prerenderedAt":266},["ShallowReactive",2],{"$foakahi6z1opl":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":58,"top_diseases":87,"top_companies":121,"key_results":151,"trends":232,"previous_editions":241,"comparison":245,"highlighted_classes":262},1,"ash-2026","ASH","ash","ASH Annual Meeting 2026",2026,"Hematology","2026-11-08T14:55:19Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},6375,3811,482,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},298,136,442,7,20,232,[24,28,32,35,37,40,44,48,52,55],{"name":25,"count":26,"share":27},"CD3",363,10,{"name":29,"count":30,"share":31},"CD19",346,9,{"name":33,"count":34,"share":20},"BCMA",263,{"name":36,"count":34,"share":20},"CD20",{"name":38,"count":39,"share":20},"BCL-2",250,{"name":41,"count":42,"share":43},"BTK",209,5,{"name":45,"count":46,"share":47},"CD38",102,3,{"name":49,"count":50,"share":51},"TOP2A",93,2,{"name":53,"count":54,"share":51},"ABL1",87,{"name":56,"count":57,"share":51},"F10",80,[59,63,67,71,75,78,81,84],{"name":60,"count":61,"share":62},"Small molecules",2207,58,{"name":64,"count":65,"share":66},"Monoclonal antibodies",737,19,{"name":68,"count":69,"share":70},"Cell therapies",620,16,{"name":72,"count":73,"share":74},"Bispecific antibodies",472,12,{"name":76,"count":77,"share":20},"Non-antibody therapeutic proteins",255,{"name":79,"count":80,"share":43},"Antibody-drug conjugates",197,{"name":82,"count":83,"share":47},"Blood, tissue and cell-derived products",124,{"name":85,"count":86,"share":51},"Oligonucleotide and RNA therapeutics",73,[88,91,95,98,102,106,109,113,116,119],{"name":89,"count":90,"share":21},"acute myeloid leukemia (AML)",773,{"name":92,"count":93,"share":94},"multiple myeloma (MM)",543,14,{"name":96,"count":97,"share":74},"diffuse large B-cell lymphoma (DLBCL)",447,{"name":99,"count":100,"share":101},"acute lymphoblastic leukemia (ALL)",296,8,{"name":103,"count":104,"share":105},"myelodysplastic syndrome (MDS)",228,6,{"name":107,"count":108,"share":43},"chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)",208,{"name":110,"count":111,"share":112},"follicular lymphoma (FL)",150,4,{"name":114,"count":115,"share":47},"sickle cell disease (SCD)",133,{"name":117,"count":118,"share":47},"mantle cell lymphoma (MCL)",116,{"name":120,"count":118,"share":47},"myelofibrosis (MF)",[122,125,128,131,134,137,140,143,145,148],{"name":123,"count":124,"share":20},"Bristol Myers Squibb",285,{"name":126,"count":127,"share":20},"AbbVie",284,{"name":129,"count":130,"share":112},"Johnson & Johnson",167,{"name":132,"count":133,"share":112},"Genentech",165,{"name":135,"count":136,"share":112},"Pfizer",148,{"name":138,"count":139,"share":47},"Novartis",118,{"name":141,"count":142,"share":51},"Sanofi",91,{"name":144,"count":54,"share":51},"Amgen",{"name":146,"count":147,"share":51},"Kite Pharma",84,{"name":149,"count":150,"share":51},"Baxter",78,[152,159,166,172,178,185,191,198,206,213,220,226],{"title":153,"drug":154,"company":129,"phase":156,"disease":92,"finding":157,"url":158},"Primary Analysis of the phase 3 randomized MonumenTAL-6 study of teclistamab (Tec) plus talquetamab (Tal) or Tal plus pomalidomide (Pom) vs investigator's choice of elotuzumab, Pom and dexamethasone (EPd) or Pom, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed\u002Frefractory multiple myeloma (RRMM) and 1–4 prior lines of therapy (LOT)",{"name":155,"slug":155},"teclistamab","Phase 3","Tec+Tal and Tal+Pom significantly improved OS vs EPd\u002FPVd (HRs [95% CI]: 0.38 [0.23–0.60], P \u003C0.0001 and 0.55 [0.36–0.83], P =0.0044, respectively).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=692431",{"title":160,"drug":161,"company":163,"phase":156,"disease":89,"finding":164,"url":165},"Superior event-free survival with ivosidenib plus intensive chemotherapy in newly diagnosed IDH1-mutated AML: Results from the phase 3 HOVON150\u002FAMLSG29-18 trial",{"name":162,"slug":162},"ivosidenib",null,"Estimated 24-mo EFS was 74% (95% CI, 67–79) with IVO vs 35% (95% CI, 28–42) with PBO.","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=695078",{"title":167,"drug":168,"company":126,"phase":156,"disease":96,"finding":170,"url":171},"Epcoritamab plus lenalidomide (E-Len) compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx): Primary results from the phase 3 EPCORE DLBCL-4 study in relapsed or refractory (R\u002FR) diffuse large B-cell lymphoma (DLBCL)",{"name":169,"slug":169},"epcoritamab","E-Len delivered a statistically significant and clinically meaningful PFS improvement vs R-GemOx with an HR of 0.40 (95% CI 0.30–0.55; P \u003C0.0001).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=684776",{"title":173,"drug":174,"company":163,"phase":156,"disease":89,"finding":176,"url":177},"Venetoclax, homoharringtonine, aclarubicin, and cytarabine (VHAA) versus daunorubicin and cytarabine (DA) as induction therapy for young adults with newly diagnosed acute myeloid leukemia: Results from a Phase III randomized controlled trial",{"name":175,"slug":175},"venetoclax","With median follow-up 35.7 vs. 37.5 months, median EFS was not reached in the VHAA group vs. 23.8 months in the DA group; 3-year EFS was 69.7% (95% CI, 60.5–77.1) vs. 47.5% (95% CI, 34.3–59.6), with a significant HR of 0.474 (95% CI, 0.280–0.805; P=0.002).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=685021",{"title":179,"drug":180,"company":163,"phase":156,"disease":182,"finding":183,"url":184},"Efficacy and safety of vamotinib versus high-dose imatinib in patients with chronic-phase CML resistant to standard-dose imatinib: 24-month Results of a multicenter randomized phase III study",{"name":181,"slug":181},"vamotinib","chronic myelogenous leukemia (CML)","MR4 was achieved in 45% vs 14% (Hazard ratio 3.84; 95% CI 2.01–7.35; p\u003C0.0001).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=685729",{"title":186,"drug":187,"company":135,"phase":156,"disease":92,"finding":189,"url":190},"Elranatamab (ELRA) monotherapy versus daratumumab plus pomalidomide and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM): Results from the phase 3 MagnetisMM-5 trial",{"name":188,"slug":188},"elranatamab","Median PFS was not reached (95% CI, 41.7-NE) for ELRA vs 27.1 (95% CI, 17.6-32.5) mo for DPd; 36-mo PFS rate was 63.5% (95% CI, 56.3-69.8) vs 41.1% (95% CI, 34.3-47.8) for ELRA and DPd, respectively.","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=695073",{"title":192,"drug":193,"company":195,"phase":156,"disease":117,"finding":196,"url":197},"Superior progression-free survival with zanubrutinib plus rituximab vs bendamustine-rituximab in treatment-naïve mantle cell lymphoma (TN MCL): Primary analysis of a phase 3 study (MANGROVE)",{"name":194,"slug":194},"zanubrutinib","BeiGene","OS, though immature at this analysis, was numerically superior with ZR over BR (HR: 0.71 [95% CI: 0.51-0.99]; 1-sided P= .0222) with 4-year OS rates of 75.1% vs 67.6%, respectively.","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=695083",{"title":199,"drug":200,"company":203,"phase":156,"disease":96,"finding":204,"url":205},"Results from the Phase 3 LOTIS-5 study: Efficacy and safety of loncastuximab tesirine plus rituximab vs immunochemotherapy (R-GemOx) in patients with relapsed or refractory DLBCL",{"name":201,"slug":202},"loncastuximab tesirine","loncastuximab-tesirine","ADC Therapeutics","Investigator-assessed PFS demonstrated an HR of 0.65 (95% CI 0.51-0.81; nominal P =0.0002; median 5.49 vs 3.02 months).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=684777",{"title":207,"drug":208,"company":163,"phase":156,"disease":210,"finding":211,"url":212},"ReSPECT: Phase 3 multicentre, randomized, double-blind study of once-weekly rezafungin versus standard antimicrobial regimen to prevent invasive fungal disease in adults undergoing allogeneic haematopoietic stem cell transplantation",{"name":209,"slug":209},"rezafungin","invasive mycoses","Time to IFD or death (Day 120) favoured rezafungin (adjusted HR 0.729 [95% CI 0.412, 1.291]).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=687480",{"title":214,"drug":215,"company":163,"phase":156,"disease":217,"finding":218,"url":219},"Final results from a phase 3 double-blind, randomized placebo-controlled study evaluating methotrexate in combination with corticosteroids as initial treatment of acute graft-versus-host disease.",{"name":216,"slug":216},"methotrexate","Acute Graft-Versus-Host Disease (aGvHD)","ORR at Day 28 was 71% versus 75% (p=0.66) and ORR at Day 56 was 65% versus 63% for methotrexate vs. placebo respectively (p=0.84).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=694320",{"title":221,"drug":222,"company":163,"phase":156,"disease":103,"finding":224,"url":225},"Final results of inspire: A Phase III international randomized controlled trial investigating rigosertib versus physician choice of treatment in patients with myelodysplastic syndromes after failure of hypomethylating agents",{"name":223,"slug":223},"rigosertib","The median overall survival was 6.37 months (95% CI: 5.78, 7.73) and 6.28 months (95% CI: 5.39, 10.05) in the rigosertib and physician choice of treatment arms, respectively (p=0.26).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=690005",{"title":227,"drug":228,"company":163,"phase":156,"disease":110,"finding":230,"url":231},"Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (B-R): Final results of the prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)",{"name":229,"slug":229},"rituximab","PFS at 10 years appeared numerically superior for 4-years versus 2-years of R-maintenance with a 10-year PFS rate of 74% vs. 69%, respectively; however this difference was not statistically significant (hazard ratio 0.82, 95% CI 0.55 – 1.22, p = 0.324).","https:\u002F\u002Fonlineprogram.hematology.org\u002Fpaper-details.aspx?pid=693327",{"summary":233,"bullets":235},[234],"Monoclonal antibodies accounted for 19% of drug-linked abstracts, up from 12% in 2025. Small molecules, the most frequent modality, accounted for 58% of drug-linked abstracts, up from 54% in 2025. Oligonucleotide and RNA therapeutics (2%) were new to the top modalities compared with 2025.",[236,237,238,239,240],"CD3 was the most frequent target (10% of drug-linked abstracts).","Acute myeloid leukemia (AML) was the most frequent disease (20%).","Bristol Myers Squibb had the largest company share (7%).","Bispecific antibodies accounted for 12% of drug-linked abstracts, up from 9% in 2025.","CD3 accounted for 10% of drug-linked abstracts, up from 8% in 2025.",[242],{"year":243,"abstracts":244},2025,8259,{"previous_year":243,"abstracts":246,"targets":249,"modalities":253,"new_in_top_targets":260,"new_in_top_modalities":261},{"previous":244,"current":13,"change_pct":247,"direction":248},23,"fell",[250],{"name":25,"count":26,"share":27,"previous_count":251,"previous_share":101,"direction":252},330,"rose",[254,256,259],{"name":64,"count":65,"share":66,"previous_count":255,"previous_share":74,"direction":252},469,{"name":60,"count":61,"share":62,"previous_count":257,"previous_share":258,"direction":252},2128,54,{"name":72,"count":73,"share":74,"previous_count":26,"previous_share":31,"direction":252},[],[85],[263,265],{"name":79,"count":80,"share":43,"previous_count":111,"previous_share":112,"direction":264},"flat",{"name":72,"count":73,"share":74,"previous_count":26,"previous_share":31,"direction":252},1794154521584]